Targeting cyclin-dependent kinase 2 (CDK2) interactions with cyclins and Speedy 1 (Spy1) for cancer and male contraception

Jeanine Giarolla; Kelsey A. Holdaway; Maryam Nazari; Laila Aiad; Bidisha Sarkar; Gunda I. Georg

doi:10.1080/17568919.2025.2463868

Targeting cyclin-dependent kinase 2 (CDK2) interactions with cyclins and Speedy 1 (Spy1) for cancer and male contraception

Jeanine Giarolla, Kelsey A. Holdaway, Maryam Nazari, Laila Aiad, Bidisha Sarkar, Gunda I. Georg

Medicinal Chemistry

Research output: Contribution to journal › Review article › peer-review

Abstract

The review discusses progress in discovering cyclin-dependent kinase 2 (CDK2) inhibitors for cancer treatment and their potential for male contraception. It summarizes first-, second-, and third-generation CDK inhibitors and selective CDK2 inhibitors currently in clinical trials for cancer. Novel strategies to discover allosteric inhibitors, covalent inhibitors, and degraders are also discussed.

Original language	English (US)
Pages (from-to)	607-627
Number of pages	21
Journal	Future Medicinal Chemistry
Volume	17
Issue number	5
DOIs	https://doi.org/10.1080/17568919.2025.2463868
State	Published - 2025

Bibliographical note

Publisher Copyright:
© 2025 Informa UK Limited, trading as Taylor & Francis Group.

Keywords

CDK2 inhibitors
Oncological therapeutics
Spy1
clinical trials
covalent binders
degraders
male contraception
orthosteric and allosteric

PubMed: MeSH publication types

Journal Article
Review

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1080/17568919.2025.2463868

Find It

Find It at U of M Libraries

Cite this

@article{07c1dfea18954eb6ad327de78ab5c49c,

title = "Targeting cyclin-dependent kinase 2 (CDK2) interactions with cyclins and Speedy 1 (Spy1) for cancer and male contraception",

abstract = "The review discusses progress in discovering cyclin-dependent kinase 2 (CDK2) inhibitors for cancer treatment and their potential for male contraception. It summarizes first-, second-, and third-generation CDK inhibitors and selective CDK2 inhibitors currently in clinical trials for cancer. Novel strategies to discover allosteric inhibitors, covalent inhibitors, and degraders are also discussed.",

keywords = "CDK2 inhibitors, Oncological therapeutics, Spy1, clinical trials, covalent binders, degraders, male contraception, orthosteric and allosteric",

author = "Jeanine Giarolla and Holdaway, {Kelsey A.} and Maryam Nazari and Laila Aiad and Bidisha Sarkar and Georg, {Gunda I.}",

note = "Publisher Copyright: {\textcopyright} 2025 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2025",

doi = "10.1080/17568919.2025.2463868",

language = "English (US)",

volume = "17",

pages = "607--627",

journal = "Future Medicinal Chemistry",

issn = "1756-8919",

publisher = "Taylor and Francis Ltd.",

number = "5",

}

TY - JOUR

T1 - Targeting cyclin-dependent kinase 2 (CDK2) interactions with cyclins and Speedy 1 (Spy1) for cancer and male contraception

AU - Giarolla, Jeanine

AU - Holdaway, Kelsey A.

AU - Nazari, Maryam

AU - Aiad, Laila

AU - Sarkar, Bidisha

AU - Georg, Gunda I.

PY - 2025

Y1 - 2025

N2 - The review discusses progress in discovering cyclin-dependent kinase 2 (CDK2) inhibitors for cancer treatment and their potential for male contraception. It summarizes first-, second-, and third-generation CDK inhibitors and selective CDK2 inhibitors currently in clinical trials for cancer. Novel strategies to discover allosteric inhibitors, covalent inhibitors, and degraders are also discussed.

AB - The review discusses progress in discovering cyclin-dependent kinase 2 (CDK2) inhibitors for cancer treatment and their potential for male contraception. It summarizes first-, second-, and third-generation CDK inhibitors and selective CDK2 inhibitors currently in clinical trials for cancer. Novel strategies to discover allosteric inhibitors, covalent inhibitors, and degraders are also discussed.

KW - CDK2 inhibitors

KW - Oncological therapeutics

KW - Spy1

KW - clinical trials

KW - covalent binders

KW - degraders

KW - male contraception

KW - orthosteric and allosteric

UR - http://www.scopus.com/inward/record.url?scp=86000235989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=86000235989&partnerID=8YFLogxK

U2 - 10.1080/17568919.2025.2463868

DO - 10.1080/17568919.2025.2463868

M3 - Review article

C2 - 40034037

AN - SCOPUS:86000235989

SN - 1756-8919

VL - 17

SP - 607

EP - 627

JO - Future Medicinal Chemistry

JF - Future Medicinal Chemistry

IS - 5

ER -

Targeting cyclin-dependent kinase 2 (CDK2) interactions with cyclins and Speedy 1 (Spy1) for cancer and male contraception

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this